Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs
Mandate

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

September 16, 2025

Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.

Sana Labs is a leading Swedish AI company offering innovative knowledge tools, primarily through two main products - Sana Learn and Sana Agents. The products offer an AI-driven training platform for companies that want to develop their employees' skills together with a personalized AI agent. The acquisition is strategically motivated and is expected to create synergies between Workday and Sana Labs through the integration of Sana Labs' AI technology into Workday's operations.

Workday is a Nasdaq-listed U.S. company and one of the largest global providers of cloud-based software solutions for managing HR and financing services.

Vinge's team consisted of, among others, Jonas Bergström, Samra Tesser, Viktor Ramhult, Johanna Barfoed and Chris Bastholm (M&A), Eva Fredrikson, Mathilda Persson, Elis Allmark and Siri Blomberg (Corporate Commercial), Sam Seddigh,  Emil Lindwall, and Louisa Fagarasan (Employment) and Malin Malm Waerme, Ian Jonson, Melinda Oldenburg (IP).

Read more: https://newsroom.workday.com/2025-09-16-Workday-Signs-Definitive-Agreement-to-Acquire-Sana

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025